Skip to content

Social Cognition Dysfunctions in Parkinson's Disease

Social Cognition Dysfunctions in Parkinson's Disease

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05230095
Acronym
cognition 2
Enrollment
24
Registered
2022-02-08
Start date
2022-04-11
Completion date
2024-01-23
Last updated
2024-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Keywords

Parkinson Disease, emotional recognition, Deep Brain Stimulation

Brief summary

Parkinson's disease (PD) is usually responsible of cognitive and behavioral non-motor signs with a major impact on the quality of life. Social cognition is a complex system relying on emotion recognition (neurons mirror system (NMS)), the theory of mind (with its two parts: emotional and cognitive), but also on the social and cultural environment and the personal history. The first step in this model is represented by the NMS, which seems to be altered in PD patients for both positive and negative emotions as shown in our preliminary study. The investigator purpose is to investigate the role of the treatment (levodopa and deep brain stimulation) on the functioning of the NMS

Interventions

BEHAVIORALsocial cognition tests

The evaluation of social cognition will be carried out using questionnaires and a point lights computer test. During the computer test, participants have to watch several short sequences of interactions between two silhouettes and give an interpretation of the scene. Patients will be evaluated twice: one time before the surgery and a second time 1 year after surgery. Healthy volunteers will be evaluated only one time.

BEHAVIORALQuality of life self-questionnaire

Quality of life will be assessed using a self-administered questionnaire in the patients group only.

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
30 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

For all participants: * Man or woman * Participant not objecting to participation in the study * Age ≥ 30 and ≤ 70 years old Specific inclusion criteria for patients: * Patients with Parkinson's disease with motor fluctuations and dyskinesias receiving deep-brain stimulation * Patients able to understand the issues of the study

Exclusion criteria

For all participants: * Person deprived of liberty by judicial or administrative decision * Person subject to a legal protection measure (tutorship, curatorship) * Person concurrently participating in another research project who may interfere with the results or conclusions of this study Specific

Design outcomes

Primary

MeasureTime frameDescription
Emotional resonance task score12 months following the inclusionIn the emotional resonance task, patients are asked to rate the emotional valence of fifteen 3-second silent videos. These movies show emotionally connoted motor interactions between two persons, each of them being depicted by 20 white dots moving on a black background (Point Light Displays (PLD) technique). Among these 15 videos, 5 has a negative valence (making someone cry, sadness, argument, hitting someone and anger), 5 has a positive valence (joy, dancing, giving a flower, laughing and cuddling) and 5 neutral valences (sit, stand, say hello, raise your arms and saw). The Emotional resonance score in parkinsonian patients undergoing treatment (dopaminergic or deep brain stimulation) will be compared to their score without treatment (OFF Dopa or OFF stimulation).

Secondary

MeasureTime frameDescription
Correlations between the emotional resonance task score and patients' quality of life self-questionnaire score (PDQ39)12 months following the inclusionPDQ39 (Parkinson's Disease Questionnaire) is a 39-item self-report questionnaire assessing Parkinsons' disease-specific health and well-being over the last month. PDQ39 provide a summary score of the impact of the illness on functioning and well-being.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026